The Tongue Squamous Carcinoma Cell Line Cal27 Primarily Employs Integrin alpha 6 beta 4-Containing Type II Hemidesmosomes for Adhesion Which Contribute to Anticancer Drug Sensitivity

Abstract

Integrins are heterodimeric cell surface glycoproteins used by cells to bind to the extracellular matrix (ECM) and regulate tumor cell proliferation, migration and survival. A causative relationship between integrin expression and resistance to anticancer drugs has been demonstrated in different tumors, including head and neck squamous cell carcinoma. Using a Cal27 tongue squamous cell carcinoma model, we have previously demonstrated that de novo expression of integrin alpha V beta 3 confers resistance to several anticancer drugs (cisplatin, mitomycin C and doxorubicin) through a mechanism involving downregulation of active Src, increased cell migration and invasion. In the integrin alpha V beta 3 expressing Cal27-derived cell clone 2B1, alpha V beta 5 expression was also increased, but unrelated to drug resistance. To identify the integrin adhesion complex (IAC) components that contribute to the changes in Cal27 and 2B1 cell adhesion and anticancer drug resistance, we isolated IACs from both cell lines. Mass spectrometry (MS)-based proteomics analysis indicated that both cell lines preferentially, but not exclusively, use integrin alpha 6 beta 4, which is classically found in hemidesmosomes. The anticancer drug resistant cell clone 2B1 demonstrated an increased level of alpha 6 beta 4 accompanied with increased deposition of a laminin-332-containing ECM. Immunofluorescence and electron microscopy demonstrated the formation of type II hemidesmosomes by both cell types. Furthermore, suppression of alpha 6 beta 4 expression in both lines conferred resistance to anticancer drugs through a mechanism independent of alpha V beta 3, which implies that the cell clone 2B1 would have been even more resistant had the upregulation of alpha 6 beta 4 not occurred. Taken together, our results identify a key role for alpha 6 beta 4-containing type II hemidesmosomes in regulating anticancer drug sensitivity.